Pane wikiwiki
Technical guide on Fmoc peptide synthesis, Nā loulou PEG, Hoʻololi kūʻē TFA, and QC thresholds for PD-L1 targeted gold nanoparticle bioconjugation.
Fmoc Peptides no PD-L1 Gula Nanoparticles: Nā kikoʻī & QC alakai
Hale Hana Cyclic Peptide ʻO ka hāʻawi ʻia ʻana o ka immune checkpoint inhibitors e hōʻike ana i kekahi o nā palena ikaika loa i ka oncology. ʻOiai nā antibodies monoclonal e kūʻē i ka Programmed Death-Ligand 1 (PD-L1) ua hoʻololi i ka mālama ʻana i ka maʻi kanesa, ʻO kā lākou hoʻokele ʻōnaehana ke kū pinepine nei i nā palena, me ke komo ʻana o ka maʻi ʻino, nā hanana ʻino e pili ana i ka immune, a me ka hoʻomaʻemaʻe wikiwiki. No ka lanakila ʻana i kēia mau pale, Ua neʻe ka noiʻi nanomedicine i nā nanoconstructs hybrid—ʻo ia hoʻi, nanoparticles gula (AuNPs) hana ʻia me nā peptides synthetic PD-L1-targeting.

Hale Hana Peptide P Hāʻawi nā nanoparticles gula i hoʻohana ʻia ʻo Peptide i ka avidity paʻa multivalent kiʻekiʻe, hoʻokaʻawale ʻia biodistribution, a me ka biocompatibility maikaʻi. Eia naʻe, ka unuhi ʻana i kahi peptide PD-L1 i hoʻolālā ʻia e ka lolouila a i ʻole phage-display-koho ʻia, ʻOi aku ka pono o ka nanoconjugate bio-functional ma mua o ka hana maʻamau solid-phase synthesis. ʻO ka holomua o ka nanoconjugation e hilinaʻi nui i nā ʻāpana kemika koʻikoʻi: lōʻihi loulou, paena-specific conjugation lima, hoʻomaʻemaʻe kūʻē, a me ka hoʻomalu ʻana i ka endotoxin.
Hōʻike kēia alakaʻi ʻenehana i nā kikoʻī o ka hopena a i ka hopena, koi 'enekinia kemika, a me ka hoomalu maikai (QC) nā manaʻolana no ka Fmoc-synthesized peptides i koho ʻia no ka conjugation nanoparticle gula.

ʻO ke Kemika o ke koho ʻana: No ke aha he mea kūpono ʻo Fmoc SPPS no PD-L1 Peptides
Hoʻohuihui Peptide Paʻa-Phase (SPSS) e hoʻohana ana i ka fluorenylmethyloxycarbonyl (Fmoc)/tert-butyl (t-Keia) ʻO ka hoʻolālā pale orthogonal e noho mau i ke kūlana gula no ka hana ʻana i nā peptides i manaʻo ʻia a hiki i ka 40-50 amino acids ka lōʻihi.. Hoʻohālikelike ʻia me ka ʻōlelo recombinant a i ʻole synthesis wai-phase, Hāʻawi ʻo Fmoc SPPS i ka mana kikoʻī kikoʻī o ka pūnaewele ma luna o ka hoʻokomo ʻana i ka waikawa amino kūlohelohe, pseudoproline dipeptides, a i hoʻopili ʻia i nā lima hoʻohui C-terminal a i ʻole N-terminal conjugation.
Ke lanakila 'ana i nā 'Obstacles Synthesis Specific Sequence-Specific Synthesis
ʻO nā peptides hoʻopaʻa PD-L1—e like me nā peptides cyclic a i ʻole linear i ʻike ʻia mai nā hale waihona puke hoʻohui ʻia—e loaʻa pinepine i nā pūpū hydrophobic waiwai i Tyrosine, Tryptophan, Phenylalanine, a me nā koena Leucine. I ka wā o ka hui kaulahao iterative ma nā kākoʻo resin insoluble (e like me Rink Amide a i ʻole nā resins Wang), ʻO kēia mau ʻāpana hydrophobic e maʻalahi i ka hōʻuluʻulu ʻana o ka pepa beta-chain. Hoʻopaʻa ʻia kēia hui ʻana i ka hiki ke komo i ka reagent, ka hoʻopau ʻole ʻana o ka Fmoc a me ka ʻoki ʻana i nā kaʻina holoi.

E hōʻoia i ka ʻoiaʻiʻo o ke kaʻina i ka wā o Fmoc SPPS:
- Hoʻopale & Nānā: Lawe ʻia ka Fmoc me ka hoʻohana ʻana 20% ʻO ka piperidine ma N,N-dimethylformamide (DMF) (v/v), nānā ʻia i ka manawa maoli ma o ka hoʻāʻo Kaiser ninhydrin e hōʻoia i ka hōʻike piha ʻana i ka amine manuahi ma mua o kēlā me kēia pōʻai hui..
- Hoʻohui Kimia: ʻO ka phosphonium kiʻekiʻe a i ʻole ka uronium coupling reagents (e like me HATU a i ʻole HBTU/Oxyma Pure) ma ke alo o N,N-diisopropylethylamine (DIPEA) Hoʻohana ʻia e hoʻokele i nā hopena hoʻohui steric a hiki i ka pau ʻana.
- Scavenger Cleavage Cocktails: Hoʻohana ka ʻokiʻoki mai ke kākoʻo resin i kahi waikawa trifluoroacetic (TFA) ʻo ka cocktail i hoʻopaʻa ʻia me nā scavengers—maʻamau TFA/Triisopropylsilane (TIS)/Wai/1,2-Etanedithiol (EDT) (92.5/2.5/2.5/2.5 v/v). Pono ka EDT a i ʻole DODT scavengers ke loaʻa nā koena Cysteine i ke kaʻina peptide, ka pale ʻana i ka hoʻopili hou ʻana o nā trityl carbocations a me ka pale ʻana i nā pūʻulu sulfhydryl manuahi mai ka oxidation premature.
Mea Hoʻohui Hoʻohui & Nā Hoʻololi Kūikawā Kūikawā no ke Kau ʻana o ke gula Nanoparticle
Pono ka hoʻopili regioselective o ka peptide i ka ʻili nanoparticle gula. Hoʻololi ka hui ʻana a i ʻole ka nui o ka pūnaewele i ka hoʻonohonoho spatial o ke kahua paʻa PD-L1., ka hoʻopaʻa ʻana i nā pharmacophores koʻikoʻi a me ka hōʻemi ʻana i ka pilina paʻa ʻana o ka mea hoʻokipa.
[PD-L1 kaʻina hoʻopaʻa] [Monodisperse PEG Linker] [Cys Thiol Handle] S AuNP

Gula-Thiol pololei (S-Au) Hoʻohui
ʻO ka sulfhydryl (–SH) pūʻulu o kahi koena Cysteine e hana i kahi ikaika, paʻa hoʻohui semi-covalent me nā ʻili gula metala, e hāʻawi ana i ka ikehu hoʻopaʻa ma kahi o 45 kcal/mol. I ka wā hoʻohuihui, Hoʻokomo ʻia kahi koena Cysteine hoʻokahi i ka pae-kūikawā ma ka C-terminus a i ʻole N-terminus o ke kaʻina.. No ka pale ʻana i ka intra- a i ʻole ka hoʻokumu ʻana o dimer disulfide inter-molecular ma mua o ka nanoconjugation, Pono e mālama ʻia nā peptides thiolated ma lalo o nā kūlana hoʻohaʻahaʻa a i ʻole mālama ʻia me nā mea hoʻemi e like me ka dithiothreitol (DTT) a i ʻole tris(2-carboxyethyl)phosphine (TCEP) ma mua o ka hoʻohui AuNP.
Polyethylene Glycol (PEG) ʻEnekinia Spacer
ʻO ka hoʻopili pololei ʻana i ka peptide hoʻopaʻa PD-L1 i ke kumu gula paʻa pinepine e hoʻokau pinepine i ka pale steric koʻikoʻi e kūʻē i ka mea hoʻokipa PD-L1 cell-surface.. No ka hoʻoponopono i kēia, he monodisperse Polyethylene Glycol (PEG) Hoʻokomo ʻia ka spacer ma waena o ke kaʻina peptide a me ka lima heleuma thiol.
Hōʻike nā palapala i paʻi ʻia he monodisperse PEG8 spacer (kaumaha molekala ~649 Da) i hoʻopili ʻia i ke kaulahao ʻaoʻao o Lysine a i ʻole pololei ma ka C-terminus e hāʻawi i ka maʻalahi spatial kūpono.. Ka noiʻi i paʻi ʻia ma PMC Bioorganic Chemistry (2024) hōʻoia i ka hoʻokomo ʻana i kahi loulou PEG8 e mālama i ka pilina paʻa kiʻekiʻe o nā peptides i hoʻopaʻa ʻia e PD-L1 ʻoiai e hoʻonui nui ana i ka hapalua o ke ola plasma a pale i ka adsorption protein non-specific. (opsonization) i ke ahiahi. Ma muli o ka curvature particle a me ka radius hydrodynamic, koho ʻia nā spacers monodisperse mai PEG2 a i PEG36 e hoʻolohe i ka nui hydrodynamic a me ka dispersibility particle..
Maleimide-Thiol Cross-Linking vs. Adsorption pololei
I ka functionalizing pre-capped gula nanoparticles (e like me citrate-stabilized a maleimide-PEG-functionalized AuNPs), Hoʻohana ʻia ʻelua ala bioconjugation ʻokoʻa:
- Hoʻololi Ligand Direct: Hoʻololi nā peptides thiolated i nā mea hana citrate capping ma luna o nā nanoparticles gula maka ma o ka hoʻokumu ʻana i ka pilina S-Au..
- Thioether Coupling: Hoʻopili nā AuNPs maleimide me nā peptide thiols manuahi e hana i kahi loulou thioether paʻa..
No ke kōkua: Ke hoʻohana nei i ka maleimide-thiol cross-linking chemistry, e mālama pono i ka pale ho'ōla i loko pH 6.5 i 7.2. Ma luna o ka pH 7.5, Nalo nā pūʻulu maleimide i ka koho no nā sulfhydryls a hoʻokūkū hoʻokūkū me nā amine kumu manuahi (e like me nā kaulahao ʻaoʻao Lysine a i ʻole N-terminal amines), hana like ole, ill-defined peptide-nanoparticle conjugates.
Hoʻomalu maikaʻi loa: Nā kikoʻī koʻikoʻi no nā Peptides i hoʻohui ʻia ʻo Nanoparticle
ʻO nā peptide i manaʻo ʻia no ka nanoconjugation ke alo i ka Mana Mana Koʻikoʻi (QC) pilikia ma mua o nā peptides noiʻi maʻamau. ʻO nā mea haumia i hiki ke hoʻohaʻahaʻa ʻia i nā hoʻokolohua biochemical maʻamau e hiki ke hoʻopilikia i ka paʻa colloidal nanoparticle., hoʻoulu i ka hoʻohui ʻia ʻana o nā mea ʻokoʻa, a i ʻole e hoʻoulu i ka cytotoxicity ʻole.
1. RP-HPLC Paepae Maʻemaʻe (≥98%)
ʻO nā kaʻina hoʻopau ʻoki ʻia e nalowale ana i hoʻokahi a ʻelua mau amino acid e loaʻa pinepine i nā profile hydropathy i hoʻololi ʻia.. I ka wā hoʻololi ligand, kēia mau pōkole, ʻO nā mea haumia holoi hydrophobic e hoʻopili pū i ka ʻili gula, ka hoʻololi ʻana i ka geometry paʻa paʻa o ka papa i manaʻo ʻia a me ka hoʻololi ʻana i ka puʻupuʻu-a-puʻu i ka avidity paʻa PD-L1. Ka liʻiliʻi loa analytical Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) maemae o ≥98% pono ka wahi piko nui. ʻImi Peptides
2. Kiekie-Resolution Mass Spectrometry (HR-LC-MS) & AAA
Pono e hōʻoia ʻia ka ʻike o ke kaʻina e LC-MS/MS, hoʻohālikelike i ka nui monoisotopic theoretical i loko o ± 0.5 Da. Eia kekahi, ʻO ke kaumaha o ka peptide nui e pili ana i ka makū a me nā counterions. ʻIkepili ʻAmina Amino (AAA) a i ʻole ka nui NMR (qNMR) pono e hooholo i ka maʻiʻo peptide net (maʻamau 75% i 85% o ke kaumaha maloo a pau), e ʻae ana i nā ʻepekema formulation e helu i nā ratio molar pololei i ka wā o ka hana nanoparticle.
3. TFA Counterion Wehe a Hoololi (<1.0% Koena)
Hoʻohana hoʻomaʻemaʻe RP-HPLC maʻamau 0.1% ʻakika trifluoroacetic (TFA) ma ke ʻano he mea hoʻololi hoʻololi. Ma ka hopena, Hoʻokaʻawale ʻia nā peptides synthetic e like me nā paʻakai TFA. ʻO ke koena TFA counterions he ʻelua pilikia nui i nā ʻōnaehana nanoparticle:
- ʻO ka hiki ʻole o Colloidal: Hoʻopilikia nā iona TFA manuahi i ka papa pālua electrostatic o nā colloids gula, ka hoʻoulu ʻana a me ka ua.
- ʻAʻawaʻawaʻawa: Hoʻokumu ke koena TFA i ka hoʻopōʻino ʻana o ka membrane cell a me ka ʻawaʻawa o nā cell i nā bioassays co-culture., pale i nā pane immunomodulatory anti-PD-L1 maoli.
Alakaʻi hoʻoponopono mai ka Keʻena Lapaʻau ʻEulopa (EMA) ma nā Peptides Synthetic ʻōlelo ʻo ia e hoʻomalu a hoʻāpono ʻia nā ʻike counterion. No ka nanoconjugation, ka hoohuli ana i na paakai TFA i acetate a i ʻole hydrochloride (HCl) ʻano paʻakai ma o ka ion-exchange chromatography a i ʻole hoʻomalu ʻia 10 ʻO nā pōʻaiapuni holoi mM HCl e hōʻemi i ke koena TFA ma lalo 1.0% w/w (hōʻoia ʻia me ka hoʻohana ʻana i ka USP <503.1> ʻAka Trifluoroacetic (TFA) i nā Peptides nā kūlana) me ka hōʻole ʻole i ke kūpaʻa kemika.
4. Endotoxin a me Bioburden Control (<0.25 EU/mg)
ʻO nā endotoxins bacteria (lipopolysaccharide, LPS) hoʻokomo ʻia i ka wā synthesis a i ʻole ka hoʻomaʻemaʻe ʻana e hoʻopaʻa ikaika i nā ʻili nanoparticle gula. Ke lawelawe ʻia ola, ʻO nā nanoconjugates i hoʻopaʻa ʻia e endotoxin e hoʻonāukiuki i nā ʻino cytokine ʻōnaehana nui a me ka hoʻoulu ʻana i ka immune., huikau i ka ʻikepili hoʻopaʻa PD-L1 preclinical. Acetyl Hexapeptide 1 Mea hana
No ka noiʻi pūnaewele, Pono nā pae endotoxin i lalo 0.5 EU/mg. No ka preclinical ola nā haʻawina, kiko'ī pili i <0.25 EU/mg (helu ʻia ma o ka chromogenic Limulus Amebocyte Lysate (LAL) nā hoʻokolohua e like me USP <85> / Ph. Eur. 2.6.14 Ho'āʻo Endotoxins Bacterial), e koi ana i ka synthesis i loko o ka mana paʻa, nā mea hana i kānana ʻia. Hoʻomohala a me ka hoʻohana ʻana i nā apo hoʻopaʻa oxidative koho me nā pūʻulu sulfhydryl he nui
Nanoparticle-Grade Peptide Quality Control Matrix
| Kūlana QC | Ke Analytical Test Method | Koina ʻae | Ka hopena o ka hana ma ka Nanoconjugation |
|---|---|---|---|
| Maemae Kemika | RP-HPLC (C18 / C8, UV 220 nm) | ≥98.0% ka hoʻoponopono ʻāina | Kāohi i ka holoi ʻana i ka haumia adsorption & heterogeneity pūnaewele paʻa |
| ʻIkepili / Mass | ESI-TOF LC-MS a i ʻole HR-MS | Nuipa Manao ± 0.5 Da | E hōʻoia i ka pololei o ke kaʻina, disulfide cyclization, & hoʻohui mea hoʻohui |
| Maʻiʻo Peptide Net | ʻIkepili ʻAmina Amino (AAA) / qNMR | 75.0% – 85.0% w/w | E hōʻoia i ka pololei stoichiometric peptide-a-gula ratio molar |
| Koe TFA maʻiʻo | Ion Chromatography / 19F-NMR (USP <503.1>) | <1.0% w/w (Kuhikuhi <0.5%) | Hoʻopau i ka hōʻuluʻulu colloid & mea ʻawaʻawa pūnaewele |
| Ka helu Thiol manuahi | ʻO Ellman's Assay (DTNB) / HPLC | ≥95.0% unoxidized –SH | Hōʻoiaʻiʻo i ka hoʻokumu ʻana i ka pilina S–Au a i ʻole ka hoʻohui maleimide |
| Endotoxin maʻi bacteria | ʻIke LAL (USP <85> / Ph. Eur. 2.6.14) | <0.25 EU/mg (ma ka papa vivo) | Kāohi i ka hoʻoikaika kino artifact & endotoxicity pūnaewele |
ʻO ke ʻano o ke kino kino ma hope o ka hoʻohui ʻana & Ho'āʻo Paʻa
Ke hoʻohui ʻia ka peptide Fmoc-synthesized kiʻekiʻe i nā nanoparticles gula, ʻO ka hōʻoia biophysical e hōʻoia i ka paʻa a paʻa ka nanoconstruct.
Peptide-AuNP Biophysical Validation Suite UV-Vis Absorption DLS & Zeta Charge Bioactivity Assay SPR Red-Shift 2-5nm Hydrodynamic Size PD-L1 Hoʻopaʻa IC50
- UV-Vis Surface Plasmon Resonance (SPR) Hoʻololi: Hōʻike ʻo Monodisperse 13-15 nm spherical gula nanoparticles i kahi kiʻekiʻe absorption SPR ikaika kokoke. 520 nm. ʻO ka hoʻokumu ʻana i kahi monolayer i hui pū ʻia me ka peptide (SAM) hoʻonui i ka ʻōlelo kuhikuhi refractive kūloko, hana i kekahi ano 2 nm i 5 nm hoʻololi ʻulaʻula (i ~522–525 nm) me ka hoʻonui ʻole ʻana. Hōʻike ka hoʻonui ʻana a i ʻole ka pau ʻana i ka hoʻohui ʻana i ka colloidal aggregation.
- Hoʻopuʻi ʻana i ka māmā (DLS) & Hiki iā Zeta: ʻIke ʻo DLS i ka piʻi ʻana o ke anawaena hydrodynamic e like me ka lōʻihi o ka pūpū ligand PEG-peptide. He Papa kuhikuhi Polydispersity (PDI) <0.2 hōʻoia i kahi monodisperse, heluna kanaka hui ole. Hōʻike ʻia ke ana ʻana o Zeta i ka hoʻololi ʻana i ka uku o ka ʻili, hōʻoia i ka uhi ʻana o ka ʻili.
- In Vitro PD-L1 Competitive Binding Assay: Hoʻopaʻa ʻia ka avidity hana ma o ELISA hoʻokūkū a i ʻole Surface Plasmon Resonance e kūʻē i ka protein PD-L1 kanaka recombinant.. Wahi a nā haʻawina ma ʻO ka PD-L1 i hoʻopaʻa ʻia i ka peptide inhibitors i paʻi ʻia ma PMC, kiʻekiʻe-avidity i hoʻopaʻa 'ia constructs loaʻa i ka hapalua-kiʻekiʻe loa hoʻopaʻa 'ia (IC50) ma ka nanomolar a hiki i ka haʻahaʻa micromolar.
⚠️ ʻŌlelo Aʻo: Mai hoʻokuʻu i nā hāʻina nanoparticle gula i hoʻohana ʻole ʻia a paʻa ʻole ʻia me ka ʻole o nā cryoprotectants kūpono. (e.g., 10% trehalose a i ʻole sucrose). ʻO ka hoʻokumu ʻia ʻana o ka hau hau e hoʻoikaika i nā core gula i ke kino kino hiki ʻole ke hoʻihoʻi ʻia, ka hoʻopaʻa ʻana metala mau loa.
Bridging Synthesis a me Nanoconjugation me nā hoʻololi MOL
ʻO ka unuhi ʻana i nā kaʻina peptide paʻakikī mai ka synthesis solid-phase i loko o ka nanoparticle therapeutics e pono ai i kahi hoa hana hana me ka ʻike hohonu cross-disciplinary i ka peptide chemistry a me ka sterile formulation..
Ma ke ʻano he kahua noiʻi a hoʻomohala kūikawā, MOL Changes hoʻohui i ka Fmoc SPPS kiʻekiʻe me nā mana bioconjugation kiʻekiʻe. Hoʻolālā ʻia e hoʻopau i ka ʻenehana ʻenehana ma waena o ka synthesis a me ka nanoconjugation, Hāʻawi nā MOL Changes: Acetyl Hexapeptide 1 Mea hoolako
- ʻO ka pololei lumi hoʻomaʻemaʻe: Hana ʻia ʻo Synthetic i loko Papa 100 nā lumi hoʻomaʻemaʻe ultra-sterile, e hōʻoia ana i nā pae endotoxin haʻahaʻa loa (<0.25 EU/mg no ka USP <85>) kūpono no nā hoʻāʻo ʻana i ke kelepona paʻakikī a ola lāʻau nanome.
- 300+ Koho Hoololi: Nā hoʻololi kikoʻī kikoʻī kikoʻī, me nā loulou PEG monodisperse (PEG2 a hiki i ka PEG36), C-terminal Cys lima, ʻO ka hoʻohana ʻana i nā kaulahao ʻaoʻao ʻo Lys, a me ka hoailona fluorophore/chelator.
- Hoʻololi ʻia ʻo TFA Exchange: Hōʻoiaʻiʻo ʻia nā kuʻina hoʻololi counterion <1.0% TFA koena (acetate a i ʻole HCl hoʻololi paʻakai i hōʻoia ʻia ma o USP <503.1> nā kūlana) kākoʻo ʻia e ka Ion Chromatography ikaika a me ka hoʻāʻo 19F-NMR.
- Paʻa i hōʻoia ʻia & hana: I nā hoʻokolohua nanoconjugation hoʻohālikelike me nā peptides PD-L1 thiolated, Ua hōʻike ʻo MOL Changes 'acetate-exchanged peptides i ka hōʻuluʻulu colloid gula ʻole ma luna o 30 mau lā ka nānā ʻana., ʻoiai ua ʻike ʻia ka ua i loko o ka paʻakai TFA i hoʻololi ʻole ʻia 48 hola.
- Scalability ʻole: Nā ʻāpana hana maʻalahi e kākoʻo ana i nā mea noiʻi mai ka nānā ʻana i ke kaʻina milligram-scale a hiki i ka nui-gram a me ka kilo CDMO/CRO pūʻulu hana..
- Hōʻoia Hoʻopaʻa Analytical: Hāʻawi ʻia kēlā me kēia pūʻulu me nā palapala analytical piha, me nā chromatograms LC-MS kiʻekiʻe, RP-HPLC maʻemaʻe profile, a me nā hopena hoʻāʻo LAL endotoxin i hōʻoia ʻia.
Inā ʻoe e hoʻolālā ana i ka hanauna hou PD-L1 i manaʻo ʻia i nā nanotherapeutics gula a i ʻole ka hoʻomohala ʻana i nā conjugates peptide-lāʻau paʻakikī. (Nā PDC), ʻO ka hui pū ʻana me kahi mea hoʻolako i hoʻolaʻa ʻenehana e hōʻoia i ka hana hou ʻana i ka hoʻokolohua a hoʻolalelale i kāu huakaʻi mai ka papa lab i ka unuhi lapaʻau..
E ʻimi i ka hoʻolālā ʻano maʻamau a me nā kikoʻī peptide mākaukau nanoconjugation i kēia lā ma ka Hoʻololi ʻo MOL i ka synthesis peptide maʻamau a me ke kahua hoʻololi.
